BioSpace News Archive

Medical device innovator NICO Corporation is the first and only provider to offer an adapter for electromagnetic navigation (EM) when performing minimally invasive parafascicular surgery (MIPS), giving neurosurgeons the choice for a frameless brain surgery procedure.

ImmunoGen, Inc. announced that on February 28, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 198,300 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.

Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Susette Gorak, who joined the Company as Senior Manager, Regulatory Affairs.

G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for an aggregate of 10,800 shares of G1’s common stock and an aggregate of 8,800 restricted stock units to four hired employees under the G1 Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive Plan.

A ketogenic diet, which primarily consists of foods like meat, fish, eggs, heavy cream, butter, oils and non-starchy vegetables like pea pods, carrots, broccoli and peppers, may be safe for people with multiple sclerosis.

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), announced today that XPOVIO®(selinexor) has been granted approval from the Health Sciences Authority (HSA) in Singapore for three indications.

Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the early participation results, as of 5:00 p.m. (New York City time) on March 1, 2022 (the “Early Tender Deadline”), of the previously announced 22 separate offers to purchase for cash notes issued by the Offerors listed in the tables below.

GRIP Molecular Technologies, Inc., an early-stage diagnostic company, announced that it has been accepted into Blue Knight, a joint initiative between Johnson and Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program.